ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements
Mankind Pharma Limited received an ESG rating of 64.8 from SES ESG Research. This rating was independently assigned for FY26 based on publicly available information.
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Mankind Pharma delivered robust Q2 growth driven by chronic therapies and B-Spec specialty expansion. Strong operating leverage and margin expansion offset muted consumer health performance.
Q2 FY27 revenue ₹4,338 Cr (+17.3% YoY), EBITDA ₹1,175 Cr (27.1% margin), PAT ₹716 Cr (+37.7%). Domestic ex-CH +15.9%, exports +32.7%, CH +1.2%.
Mankind Pharma reported Q2 FY27 revenue of ₹4,338 Cr, up 17% YoY, and PAT of ₹716 Cr, up 38%. EBITDA margin improved 210 bps to 27.1%.
Mankind Pharma's board approved amalgamation of two wholly owned subsidiaries into the parent and a step-down subsidiary merger into MCPPL. Schemes require NCLT and shareholder approvals.
Mankind Pharma Ltd reported revenue from operations of ₹4,338 Cr (+17.3% YoY) and net profit of ₹716.1 Cr (+37.7% YoY) for Q2 FY27.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Mankind Pharma has successfully completed the interest payment and full redemption of its Non-Convertible Debentures due on October 16, 2026.
Mankind Pharma has fully redeemed its Non-Convertible Debentures, paying back the principal amount of ₹1,250 Crore on the maturity date.
Mankind Pharma Ltd confirmed payment of interest for its non-convertible debentures. This routine debt servicing update confirms the company has fulfilled its payment obligations.
Mankind Pharma will invest ₹479.60 Crore into its Dutch subsidiary to acquire a majority 70% stake in Belgian biotech firm ACTx, strengthening its innovation-led portfolio.
Mankind Pharma will acquire a 70% stake in Belgium-based Armed Cell Therapeutics for EUR 48 million to enter the CAR-T therapies market.
Mankind Pharma Ltd will hold a Board meeting on October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results.
S.R. Batliboi & Co. LLP resigned as statutory auditors of Bharat Serums and Vaccines Limited, a material subsidiary of Mankind Pharma. The resignation follows voluntary liquidation proceedings.
Mankind Pharma announced the successful passing of a special resolution to appoint Mr. Anish Vanraj Bafna as a Non-Executive Independent Director. The Postal Ballot concluded with the required majority.
Mankind Pharma has been assigned an ESG rating of 68.21 ('Leader' category) by Niche99 ESG Ratings, based on publicly available data for FY 2025-26.
Mankind Pharma announced that members of its wholly-owned subsidiary, Bharat Serums and Vaccines Limited (BSVL), approved its voluntary liquidation in an EGM.
Mankind Pharma has allotted 49,112 equity shares under its ESOP Plan 2022 to eligible employees upon exercise of options. The allotment increases its paid-up share capital.
Mankind Pharma has allotted 49,112 equity shares under its ESOP scheme. This allotment increases the paid-up share capital by Rs. 49,112 in face value.
Mankind Pharma announced the cessation of Mr. Bharat Anand as an Independent Director, effective August 30, 2026, upon the completion of his second term.
Mankind Pharma's board approved the voluntary liquidation of its subsidiary, Bharat Serums and Vaccines Limited, to integrate its business into the parent company.
Mankind Pharma has received an improved ESG rating of 64 from CRISIL, categorized as 'Strong'. The rating was assigned independently without company engagement.
Mankind Pharma entered an exclusive in-licensing and marketing agreement with Chongqing Chenan Biopharmaceutical Co., Ltd. The deal covers commercialisation of insulin analogues in India.
Mankind Pharma Limited has issued a Postal Ballot Notice to seek shareholder approval for the appointment of Mr. Anish Vanraj Bafna as a Non-Executive Independent Director.
Mankind Pharma has completed the realignment of security cover for its NCDs. Consequently, it has released the pledge on 28,280 shares of Bharat Serums and Vaccines.
Mankind Pharma has incorporated a wholly-owned subsidiary in the Netherlands, "Mankind Pharma (Netherlands) B.V.", with an issued capital of ₹55.06 Crore.
Mankind Pharma has incorporated a wholly-owned subsidiary, 'Mankind Pharma (Netherlands) B.V.', in the Netherlands as previously disclosed.
Mankind Pharma has appointed Mr. Anish Vanraj Bafna as an Additional Director (Non-Executive Independent Director), effective August 10, 2026.
Mankind Pharma held its 35th Annual General Meeting on August 4, 2026. The meeting covered routine business, including the adoption of financial statements and director re-appointments.